Search results
Merck stopped a clinical trial for its experimental skin cancer drug after a high rate of side...
Quartz· 3 days agoThe study was testing whether a combination of the company’s flagship cancer drug Keytruda and its...
Merck stops testing combo drug for skin cancer as more patients discontinue
Reuters via Yahoo News· 3 days agoThis is the latest setback for the experimental drug, vibostolimab, and the related promising new...
Merck Halts Skin Cancer Drug Trial On High Discontinuation Rate - A Setback in High-Risk Melanoma...
Benzinga· 3 days agoThe trial evaluates the investigational coformulation of vibostolimab and Keytruda (pembrolizumab)...
Merck (MRK) Ends Keytruda Combo Melanoma Study Due to Futility
Zacks via Yahoo Finance· 2 days agoNumerous recent approvals and the expected launch of many additional indications, including in...
Merck stops skin cancer combination therapy testing in late-stage study
WHTC 1450 Holland· 3 days ago(Reuters) -Merck has discontinued testing a combination of an experimental antibody-based drug and...
Merck Ends Co-Formulation Arm of Keytruda High-Risk Melanoma Study
Morningstar· 3 days agoMerck & Co. has ended part of a late-stage study of a co-formulation of its blockbuster cancer drug Keytruda in certain skin-
Merck halts research on combo drug for skin cancer
Becker’s Hospital Review· 3 days agoMerck will stop testing an experimental combination treatment for skin cancer patients in a late-stage study, the drugmaker said May 13. Merck was evaluating the use of the ...
Merck Study of Keytruda With Chemotherapy in Endometrial Cancer Fails to Meet Endpoint
Morningstar· 7 days agoMerck was hit with a setback in its efforts to expand its blockbuster cancer immunotherapy Keytruda after a late-stage study of its use in combination with ...
Merck’s trial of KEYTRUDA regimen fails to meet primary endpoint
Clinical Trials Arena via Yahoo Finance· 6 days agoEarlier this month, Merck reported the final analysis findings from the Phase III KEYNOTE-811 trial...
2 No-Brainer Dividend Stocks to Buy in May
Motley Fool via Yahoo Finance· 7 days agoThe oncology market is known for its strong pricing power, with cancer drugs typically carrying high price tags and significant margins. While Pfizer's...
